--- title: "Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential" type: "News" locale: "en" url: "https://longbridge.com/en/news/286284525.md" description: "Analyst Oliver McCammon from LifeSci Capital has reiterated a Buy rating on Corbus Pharmaceuticals, maintaining a price target of $38. He believes Corbus's CRB-701 has significant potential in treating HPV-positive head and neck cancer, an underserved market. McCammon anticipates upcoming Phase 1/2 data to validate this outlook. He also notes Corbus's strong cash position supports ongoing development without immediate financing needs. Oppenheimer has similarly reiterated a Buy rating with a higher price target of $54. McCammon is recognized as a 5-star analyst with a strong track record in the Healthcare sector." datetime: "2026-05-13T15:05:38.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286284525.md) - [en](https://longbridge.com/en/news/286284525.md) - [zh-HK](https://longbridge.com/zh-HK/news/286284525.md) --- # Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential Oliver McCammon, an analyst from LifeSci Capital, maintained the Buy rating on Corbus Pharmaceuticals. The associated price target remains the same with $38.00. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Oliver McCammon has given his Buy rating due to a combination of factors tied to Corbus’s emerging oncology franchise and the strategic positioning of CRB-701. He views HPV-positive head and neck cancer as an underserved, expanding segment where current EGFR‑targeted bispecific antibodies in late‑stage studies appear ill‑suited, particularly given their exclusion of HPV‑positive patients or weaker activity in that subgroup. McCammon believes this creates a meaningful opening for an alternative modality like anetumab ravtansine‑based ADC CRB‑701, which mechanistically aligns with the cyclin‑driven biology of HPV‑positive tumors and could be better tolerated in a generally younger, fitter patient population. He expects upcoming Phase 1/2 data for CRB‑701, including at ASCO, to refine the risk‑reward profile and potentially validate this thesis, while also recognizing that investor interest is already building around the HPV‑positive HNSCC opportunity. In his view, Corbus’s cash position and burn rate provide an adequate runway to reach key value‑inflection points, supporting continued development of CRB‑701 and the broader pipeline without immediate financing pressure. Reflecting confidence in both the clinical strategy and market opportunity, McCammon reiterates a Buy rating and maintains his 12‑month price target at $38, unchanged from his prior valuation. According to TipRanks, McCammon is a 5-star analyst with an average return of 95.0% and a 67.92% success rate. McCammon covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Monte Rosa Therapeutics, and Corbus Pharmaceuticals. In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $54.00 price target. ### Related Stocks - [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [CATX.US](https://longbridge.com/en/quote/CATX.US.md) - [GLUE.US](https://longbridge.com/en/quote/GLUE.US.md) - [OPY.US](https://longbridge.com/en/quote/OPY.US.md) ## Related News & Research - [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md) - [Brokers Offer Predictions for CRBP Q2 Earnings](https://longbridge.com/en/news/286408539.md) - [RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/286342985.md) - [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md) - [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)